

Sabril[®] (vigabatrin) – Expanded indication

- On January 24, 2020, the <u>FDA approved</u> Lundbeck's <u>Sabril (vigabatrin)</u>, as adjunctive therapy for
 adults and pediatric patients 2 years of age and older with refractory complex partial seizures who
 have inadequately responded to several alternative treatments and for whom the potential benefits
 outweigh the risk of vision loss.
 - Sabril was previously approved for this indication in patients 10 years of age and older.
 - Sabril is not indicated as a first line agent for complex partial seizures.
- Sabril is also approved as monotherapy for pediatric patients with infantile spasms 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss.
- The safety and effectiveness of Sabril as adjunctive treatment of refractory complex partial seizures in pediatric patients 2 to 16 years of age have been established and is supported by three double-blind, placebo-controlled studies in patients 3 to 16 years of age, adequate and well-controlled studies in adult patients, pharmacokinetic data from patients 2 years of age and older, and additional safety information in patients 2 years of age.
- Sabril carries a boxed warning for permanent vision loss.
- The recommended dose of Sabril for the treatment of refractory complex partial seizures in pediatric
 patients (2 to 16 years of age) is based on body weight and administered as two divided doses. The
 dosage may be increased in weekly intervals to the total daily maintenance dosage, depending on
 response.

Body weight (kg)	Total daily starting dose (mg/day)	Total daily maintenance dose (mg/day)
10 kg to 15 kg	350 mg	1050 mg
> 15 kg to 20 kg	450 mg	1300 mg
> 20 kg to 25 kg	500 mg	1500 mg
> 25 kg to 60 kg	500 mg	2000 mg

- Sabril should be withdrawn if a substantial clinical benefit is not observed within 3 months of
 initiating treatment. If, in the clinical judgment of the prescriber, evidence of treatment failure
 becomes obvious earlier than 3 months, treatment should be discontinued at that time.
- Refer to the Sabril drug label for dosing in adults and for its other indication.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.